Recent FDA approvals
- Tirzepatide for OSA (2024)
- Semaglutide cardiovascular label expansion (2024)
- Tirzepatide for HFpEF (under review)
Late-stage candidates
- Retatrutide (triple agonist)
- Orforglipron (oral non-peptide GLP-1)
- Survodutide (GLP-1/glucagon dual)
- CagriSema (amylin + GLP-1)
When for retatrutide?
Phase 3 results 2026, approval likely 2027-2028.